REVVITY, INC. is 3.0x more valuable than 10x Genomics, Inc. by market capitalization ($11.30 B vs $3.72 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | TXG | RVTY |
|---|---|---|
| Market cap | $3.72 B | $11.30 B |
| US-listed rank | #1634 | #873 |
| Revenue (latest FY) | $642.82M | $2.86B |
| Net income (latest FY) | -$43.50M | $241.20M |
| Net margin | -6.8% | 8.4% |
| P/E (trailing FY) | - | 46.8 |
| SEC filings | 652 | 1,736 |
REVVITY, INC. is 3.0x more valuable than 10x Genomics, Inc. by market capitalization ($11.30 B vs $3.72 B).
In their latest fiscal years, 10x Genomics, Inc. reported $642.82M in revenue while REVVITY, INC. reported $2.86B.
Full pages: 10x Genomics, Inc. and REVVITY, INC., or browse the full rankings.